Walleye Capital’s Oramed Pharmaceuticals ORMP Stock Holding History

Walleye Capital’s Portfolio ORMP Stock Details ORMP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-36,102	Closed	-$78.7K	–	4744
2023 Q1	$78.7K	Buy	+36,102	New	+$115K	﹤0.01%	3046
2022 Q4	–	Sell	-78,418	Closed	-$508K	–	3511
2022 Q3	$508K	Buy	+78,418	New	+$635K	0.01%	1457
2022 Q1	–	Sell	-36,740	Closed	-$525K	–	2509
2021 Q4	$525K	Buy	+36,740	New	+$768K	0.02%	958

Other funds holding ORMP

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Walleye Capital's ORMP Position: Q2 2023 in Review

Walleye Capital sold out of Oramed Pharmaceuticals (ORMP) in Q2 2023, closing a stake of 36,102 shares — an estimated $78.7K sold.

Walleye Capital first reported a position in ORMP in Q4 2021 and held it in 3 quarters. The position peaked at $525K in Q4 2021. 50 funds tracked by Wall St. Rank hold ORMP as of Q2 2023.

Walleye Capital reported no remaining Oramed Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
Walleye Capital sold 36,102 Oramed Pharmaceuticals shares in Q2 2023, an estimated $78.7K.
Walleye Capital first reported a position in Oramed Pharmaceuticals in Q4 2021 and held it in 3 quarters.
Walleye Capital's Oramed Pharmaceuticals position peaked at $525K in Q4 2021.
50 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q2 2023.

Based on Walleye Capital's 13F filing for Q2 2023, filed 14 Aug 2023.